ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

27 links0 made here, not in the record60 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govReplaced, or read an older version
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT04591431The Rome Trial FromHistology to Target: theRoad to Personalize TargetTherapy and ImmunotherapyFondazione per la Medicina PerPhase 2 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedCONDITIONSBreast NeoplasmsThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionGastrointestinal NeoplasmsThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.Carcinoma, Non-Small-Cell L…The registry's MeSH filing›No judgment recorded. Shown as the registry files it.DRUGSErlotinibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundTrastuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundAdo-Trastuzumab EmtansineEntry “Trastuzumab emtansine”, read b…›Nov 2 · Claude Opus 5.5 · BackgroundNov 10 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · BackgroundBackground · optionPertuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 10 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · BackgroundBackground · optionLapatinibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundEverolimusIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundVemurafenibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCobimetinibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 10 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · BackgroundBackground · optionAlectinibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 10 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · BackgroundBackground · optionBrigatinibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundPalbociclibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 10 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · BackgroundBackground · optionPonatinibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundItacitinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedIpatasertibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 10 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · TestedBackground · optionEntrectinibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 10 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · BackgroundBackground · optionAtezolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 10 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · BackgroundBackground · optionNivolumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 10 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · BackgroundBackground · optionIpilimumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 10 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · BackgroundBackground · optionPemigatinibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundPralsetinibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundSelpercatinibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundTalazoparibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundTepotinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAlpelisibIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 10 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · BackgroundBackground · option

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Erlotinib

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Erlotinib”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Background
Background · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2ErlotinibClaude Opus 5.5BackgroundCurrent
Nov 2TrastuzumabClaude Opus 5.5BackgroundCurrent
Nov 2Ado-Trastuzumab EmtansineClaude Opus 5.5BackgroundReplaced
Nov 2PertuzumabClaude Opus 5.5BackgroundReplaced
Nov 2LapatinibClaude Opus 5.5BackgroundCurrent
Nov 2EverolimusClaude Opus 5.5BackgroundCurrent
Nov 2VemurafenibClaude Opus 5.5BackgroundCurrent
Nov 2CobimetinibClaude Opus 5.5BackgroundReplaced
Nov 2AlectinibClaude Opus 5.5BackgroundReplaced
Nov 2BrigatinibClaude Opus 5.5BackgroundCurrent
Nov 2PalbociclibClaude Opus 5.5BackgroundReplaced
Nov 2PonatinibClaude Opus 5.5BackgroundCurrent
Nov 2ItacitinibClaude Opus 5.5TestedCurrent
Nov 2IpatasertibClaude Opus 5.5TestedReplaced
Nov 2EntrectinibClaude Opus 5.5BackgroundReplaced
Nov 2AtezolizumabClaude Opus 5.5BackgroundReplaced
Nov 2NivolumabClaude Opus 5.5BackgroundReplaced
Nov 2IpilimumabClaude Opus 5.5BackgroundReplaced
Nov 2PemigatinibClaude Opus 5.5BackgroundCurrent
Nov 2PralsetinibClaude Opus 5.5BackgroundCurrent
Nov 2SelpercatinibClaude Opus 5.5BackgroundCurrent
Nov 2TalazoparibClaude Opus 5.5BackgroundCurrent
Nov 2TepotinibClaude Opus 5.5TestedCurrent
Nov 2AlpelisibClaude Opus 5.5BackgroundReplaced
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 10Ado-Trastuzumab EmtansineClaude Opus 5.5Background · optionCurrent
Nov 10PertuzumabClaude Opus 5.5Background · optionCurrent
Nov 10CobimetinibClaude Opus 5.5Background · optionCurrent
Nov 10AlectinibClaude Opus 5.5Background · optionCurrent
Nov 10PalbociclibClaude Opus 5.5Background · optionCurrent
Nov 10IpatasertibClaude Opus 5.5Background · optionCurrent
Nov 10EntrectinibClaude Opus 5.5Background · optionCurrent
Nov 10AtezolizumabClaude Opus 5.5Background · optionCurrent
Nov 10NivolumabClaude Opus 5.5Background · optionCurrent
Nov 10IpilimumabClaude Opus 5.5Background · optionCurrent
Nov 10AlpelisibClaude Opus 5.5Background · optionCurrent
Nov 18ErlotinibRule based · role ruleBackgroundAgrees
Nov 18TrastuzumabRule based · role ruleBackgroundAgrees
Nov 18Ado-Trastuzumab EmtansineRule based · role ruleBackgroundAgrees
Nov 18PertuzumabRule based · role ruleBackgroundAgrees
Nov 18LapatinibRule based · role ruleBackgroundAgrees
Nov 18EverolimusRule based · role ruleBackgroundAgrees
Nov 18VemurafenibRule based · role ruleBackgroundAgrees
Nov 18CobimetinibRule based · role ruleBackgroundAgrees
Nov 18AlectinibRule based · role ruleBackgroundAgrees
Nov 18BrigatinibRule based · role ruleBackgroundAgrees
Nov 18PalbociclibRule based · role ruleBackgroundAgrees
Nov 18PonatinibRule based · role ruleBackgroundAgrees
Nov 18ItacitinibRule based · role ruleTestedAgrees
Nov 18IpatasertibRule based · role ruleTestedOverridden
Nov 18EntrectinibRule based · role ruleBackgroundAgrees
Nov 18AtezolizumabRule based · role ruleBackgroundAgrees
Nov 18NivolumabRule based · role ruleBackgroundAgrees
Nov 18IpilimumabRule based · role ruleBackgroundAgrees
Nov 18PemigatinibRule based · role ruleBackgroundAgrees
Nov 18PralsetinibRule based · role ruleBackgroundAgrees
Nov 18SelpercatinibRule based · role ruleBackgroundAgrees
Nov 18TalazoparibRule based · role ruleBackgroundAgrees
Nov 18TepotinibRule based · role ruleTestedAgrees
Nov 18AlpelisibRule based · role ruleBackgroundAgrees
As of nowBreast NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.